Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1950 1
1954 1
1955 1
1957 1
1958 1
1959 2
1960 2
1962 2
1963 4
1964 4
1965 2
1966 4
1967 2
1968 1
1969 1
1970 3
1971 2
1972 2
1973 4
1974 2
1975 5
1976 2
1977 1
1978 6
1979 8
1980 6
1981 8
1982 6
1983 7
1984 7
1985 4
1986 5
1987 11
1988 11
1989 13
1990 11
1991 12
1992 6
1993 9
1994 9
1995 5
1996 4
1997 8
1998 4
1999 16
2000 8
2001 9
2002 19
2003 20
2004 14
2005 15
2006 22
2007 16
2008 25
2009 20
2010 27
2011 35
2012 30
2013 26
2014 26
2015 37
2016 26
2017 28
2018 28
2019 31
2020 47
2021 64
2022 64
2023 50
2024 49
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

885 results

Results by year

Filters applied: . Clear all
Page 1
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.
Klomp JE, Diehl JN, Klomp JA, Edwards AC, Yang R, Morales AJ, Taylor KE, Drizyte-Miller K, Bryant KL, Schaefer A, Johnson JL, Huntsman EM, Yaron TM, Pierobon M, Baldelli E, Prevatte AW, Barker NK, Herring LE, Petricoin EF 3rd, Graves LM, Cantley LC, Cox AD, Der CJ, Stalnecker CA. Klomp JE, et al. Among authors: diehl jn. Science. 2024 Jun 7;384(6700):eadk0850. doi: 10.1126/science.adk0850. Epub 2024 Jun 7. Science. 2024. PMID: 38843329 Free PMC article.
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
Pan Y, Han H, Hu H, Wang H, Song Y, Hao Y, Tong X, Patel AS, Misirlioglu S, Tang S, Huang HY, Geng K, Chen T, Karatza A, Sherman F, Labbe KE, Yang F, Chafitz A, Peng C, Guo C, Moreira AL, Velcheti V, Lau SCM, Sui P, Chen H, Diehl JA, Rustgi AK, Bass AJ, Poirier JT, Zhang X, Ji H, Zhang H, Wong KK. Pan Y, et al. Among authors: diehl ja. Cancer Cell. 2023 Jan 9;41(1):88-105.e8. doi: 10.1016/j.ccell.2022.11.015. Epub 2022 Dec 15. Cancer Cell. 2023. PMID: 36525973 Free PMC article.
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
Klomp JA, Klomp JE, Stalnecker CA, Bryant KL, Edwards AC, Drizyte-Miller K, Hibshman PS, Diehl JN, Lee YS, Morales AJ, Taylor KE, Peng S, Tran NL, Herring LE, Prevatte AW, Barker NK, Hover LD, Hallin J, Sorokin A, Kanikarla PM, Chowdhury S, Coker O, Lee HM, Goodwin CM, Gautam P, Olson P, Christensen JG, Shen JP, Kopetz S, Graves LM, Lim KH, Wang-Gillam A, Wennerberg K, Cox AD, Der CJ. Klomp JA, et al. Among authors: diehl jn. Science. 2024 Jun 7;384(6700):eadk0775. doi: 10.1126/science.adk0775. Epub 2024 Jun 7. Science. 2024. PMID: 38843331 Free PMC article.
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors.
Zhang H, Yu P, Tomar VS, Chen X, Atherton MJ, Lu Z, Zhang HG, Li S, Ortiz A, Gui J, Leu NA, Yan F, Blanco A, Meyer-Ficca ML, Meyer RG, Beiting DP, Li J, Nunez-Cruz S, O'Connor RS, Johnson LR, Minn AJ, George SS, Koumenis C, Diehl JA, Milone MC, Zheng H, Fuchs SY. Zhang H, et al. Among authors: diehl ja. Nat Cancer. 2022 Jul;3(7):808-820. doi: 10.1038/s43018-022-00383-0. Epub 2022 May 30. Nat Cancer. 2022. PMID: 35637402 Free PMC article.
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.
Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ. Bryant KL, et al. Among authors: diehl jn. Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4. Nat Med. 2019. PMID: 30833752 Free PMC article.
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D.
Chaikovsky AC, Li C, Jeng EE, Loebell S, Lee MC, Murray CW, Cheng R, Demeter J, Swaney DL, Chen SH, Newton BW, Johnson JR, Drainas AP, Shue YT, Seoane JA, Srinivasan P, He A, Yoshida A, Hipkins SQ, McCrea E, Poltorack CD, Krogan NJ, Diehl JA, Kong C, Jackson PK, Curtis C, Petrov DA, Bassik MC, Winslow MM, Sage J. Chaikovsky AC, et al. Among authors: diehl ja. Nature. 2021 Apr;592(7856):794-798. doi: 10.1038/s41586-021-03474-7. Epub 2021 Apr 14. Nature. 2021. PMID: 33854239 Free PMC article.
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF 3rd, Cox AD, Bryant KL, Der CJ. Klomp JE, et al. Among authors: diehl jn. Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060. Cell Rep. 2021. PMID: 34852220 Free PMC article.
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.
Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, Anderson AO, Waters AM, Diehl JN, Papke B, Hodge RG, Klomp JE, Goodwin CM, DeLiberty JM, Wang J, Ng RWS, Gautam P, Bryant KL, Esposito D, Campbell SL, Petricoin EF 3rd, Simanshu DK, Aguirre AJ, Wolpin BM, Wennerberg K, Rudloff U, Cox AD, Der CJ. Hobbs GA, et al. Among authors: diehl jn. Cancer Discov. 2020 Jan;10(1):104-123. doi: 10.1158/2159-8290.CD-19-1006. Epub 2019 Oct 24. Cancer Discov. 2020. PMID: 31649109 Free PMC article.
885 results